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Abstract: Immune thrombocytopenic purpura (ITP) is a relatively common autoimmune 
disorder in which antibodies are produced to circulating platelets. Symptoms can be mild, but 
for most patients the risk of severe bleeding is unacceptable and treatment is required. Gluco-
corticoids followed by splenectomy had been the mainstays of therapy. High dose intravenous 
immunoglobulin and anti-RhD therapy are available for patients with severe illness, but pro-
duce only temporary beneﬁ  t. Rituximab may provide more durable responses, danazol may be 
underutilized, and immunosuppressants and cytotoxic agents are less often required. Recently 
the pathophysiology of ITP has been more clearly elucidated, particularly the importance of 
decreased production of platelets in most patients and the very blunted rise that occurs in serum 
thrombopoietin (TPO). The isolation of TPO and better understanding of its role in thrombo-
poiesis has led to the development of new highly effective treatments. TPO analogs had some 
successes in treating highly refractory ITP patients but were taken out of development due to 
TPO-antibody induction. Two second-generation TPO-mimetics, romiplostim and the orally 
available eltrombopag, have recently been licensed in some territories for the treatment of ITP. 
Approval of eltrombopag was based on results from Phase II and III placebo-controlled clinical 
trials and a long-term extension study. About 80% of patients achieve signiﬁ  cant increases in 
platelet count (11% of placebo patients), with reduced bleeding and reduced use of concomitant 
medications; responses are often durable with no tachyphylaxis. The side effects of eltrombopag 
are generally mild and not worse than placebo, although there are concerns about hepatic dys-
function, and the potentials for thromboses, marrow reticulin ﬁ  brosis, rebound thrombocytopenia 
and cataracts. This is an important new option for highly refractory patients, and its niche in 
earlier treatment (and for other thrombocytopenic disorders) is yet to be deﬁ  ned.
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Introduction
When a teenage girl presented to a Boston hospital in 1945 with bleeding and severe 
thrombocytopenia, splenectomy was the only known treatment for immune throm-
bocytopenic purpura (ITP). She was dispatched to the operating room but died from 
surgical bleeding. This case so profoundly affected a medical student, William Har-
rington, that he resolved to pursue a career in hematology studying ITP.1 There were 
reasons to suspect that ITP was due to autoantibodies directing the rapid clearance 
of platelets from the circulation, and Harrington dramatically advanced this theory 
in 1950 by self-injecting plasma from an ITP patient. His platelet count plummeted, 
accompanied by petechiae and seizure. Transient thrombocytopenia was then repro-
duced by giving ITP plasma to various categories of volunteers.2 We now know that 
pathogenic IgG anti-platelet autoantibodies are most often directed against GpIIb-IIIa 
or GpIb-IX epitopes.3
By the mid 1980s, ITP therapy had become straightforward because the patho-
genesis was believed to be fully elucidated, the paradigm for humorally-mediated Biologics: Targets & Therapy 2009:3 152
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autoimmune disease. Glucocorticoid therapies had been 
developed which paralyzed reticuloendothelial cells that 
phagocytized antibody-coated platelets, impaired the bind-
ing of autoantibody to platelet antigens and, less reliably, 
diminished the synthesis of anti-platelet antibodies. Steroids 
were highly effective initially, but the great majority of 
patients relapsed as the dose was tapered to levels tolerable 
for the long-term. At that point, splenectomy was performed, 
impacting the accelerated platelet destruction by removing 
the major reticuloendothelial organ responsible for platelet 
clearance, and also a major site for autoantibody production. 
Short- and long-term disease control were thus achieved in 
most patients. More potent and toxic immunosuppressive 
agents, such as cyclophosphamide, vincristine and azathio-
prine, were used to salvage refractory patients.
In the last two decades, management decisions for ITP 
have become more complex as new treatment options have 
emerged. While these options generally achieve disease con-
trol, therapy has become more costly and potential toxicities 
remain problematic. The individual preferences of patients 
and their physicians have replaced standard treatment algo-
rithms. This is especially true because of a lack of evidence 
from quality clinical trials, so guidance for clinicians hinges 
on the vagaries of expert “consensus” opinions.4
The disease and current treatments
ITP is an autoimmune disorder manifest as thrombocytope-
nia related to the production of antibodies against platelet 
antigens. It is relatively common in any hematology refer-
ral practice, with estimated prevalence 300,000 to 600,000 
among adults in the US.5–7 Terminology can be confusing 
and inconsistent: many separate “secondary ITP” from the 
primary idiopathic form. Secondary ITP may be seen with 
systemic lupus erythematosus, anti-phospholipid antibodies, 
HIV, hepatitis C, Helicobacter pylori, lymphoproliferative 
and other disorders. Several of these are routinely screened 
for in a patient with isolated thrombocytopenia. The patho-
physiology and management decisions with some of these 
disorders may be the same as with idiopathic ITP. On the 
other hand, “childhood ITP,” often called “acute ITP,” 
behaves differently. Childhood ITP occurs almost as fre-
quently as adult ITP, often follows a viral infection, and usu-
ally resolves within 2 months even without therapy. Opinions 
vary on when and how to treat childhood ITP, with studies 
challenged by the low incidence of serious morbidity and 
mortality.8 Childhood ITP is not further discussed herein.
A minority of patients with ITP have only mild asymp-
tomatic thrombocytopenia which requires no therapy and 
may remain stable for years or spontaneously remit. For most 
patients, platelet levels below 30 × 109/L indicate an unac-
ceptable risk of bleeding and so treatment is mandated.
Corticosteroids are the mainstay of initial therapy, with 
prednisone 1 mg/kg daily widely employed. Platelets rise to 
a safe level in more than 80% to 90% of patients. However, 
platelet counts fall back in 90% of responders as the steroids 
are tapered. It is an art of the practitioner to transition ITP 
patients off corticosteroids to other modes of disease control 
before cumulative steroid toxicities become onerous. Some 
recent studies have advocated high dose pulses of dexametha-
sone to achieve durable remissions with lessened toxicity,9,10 
but this has not gained widespread popularity. The most 
recent multi-center trial found long-term disease control in 
only 39% (see rituximab below).11
Opinions vary widely among experts on when and for 
how long to employ high-dose intravenous immunoglobulin 
(IVIG) or anti-RhD. In my practice, IVIG is reserved for 
unusually severe cases (substantial mucosal and other bleed-
ing; platelets 5 × 109/L or less) or special circumstances such 
as pregnancy or pre-operative. The same applies to anti-D 
therapy for the 80% of the population who are RhD positive 
and have intact spleens. An advantage of these therapies is 
rapid action, often increasing platelets within a couple of 
days in the 80% who are responsive. The main drawback, 
besides expense, is that responses are generally very transient, 
platelets generally returning to baseline levels in 3 weeks. 
IVIG therapy entails repeated prolonged intravenous infu-
sions, infusional reactions, renal toxicities and, more rarely, 
aseptic meningitis and thrombotic reactions. Anti-D causes 
some degree of hemolytic anemia, uncommonly severe.12
To maintain remission as steroids are tapered, reasonable 
options are splenectomy, danazol or rituximab. A decade ago, 
most adults underwent splenectomy for long-term disease 
control, often performed sooner rather than later. A recent 
trend is to reserve surgery for patients who have failed two 
or more therapies. Splenectomy may also be delayed because 
of the increasingly recognized possibility of spontaneous 
remissions, even late, something that also colors the indi-
cations and interpretation of results for other therapies.13 
Nevertheless, results are as good as ever, with 10% to 40% 
never requiring additional therapies.14 The availability of 
laparoscopic surgery reduces immediate morbidity,15 but 
there is lifelong increased risk for serious infection by 
encapsulated organisms.
Rituximab, an anti-CD20 monoclonal antibody, is increas-
ingly popular as a second-line therapy. Overall responses are 
obtained in 53% to 69% of patients, with complete responses Biologics: Targets & Therapy 2009:3 153
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in 33% to 54%, usually beginning about 3 weeks after therapy 
initiation.16–18 The only common side-effects are infusional 
reactions. The medication is expensive, but responses are 
often durable, with one study ﬁ  nding that two-thirds of remit-
ting patients are still in remission at 5.8 years,19 and another 
ﬁ  nding 5-year relapse-free and treatment-free survivals of 
72% and 61%.18 In a recently completed randomized trial, 
a strategy of an initial dexamethasone pulse with rituximab 
led to sustained responses in 85% of ITP patients, more than 
twice the rate with dexamethasone alone.11
Danazol, an attenuated androgen, has been successfully 
used for ITP for more than 25 years, yet is another therapy 
that engenders particularly diverse expert opinions.4 Some 
believe it underutilized, producing responses in two-thirds 
of patients in large published case series, including half of 
patients with highly refractory disease. Responses are often 
durable, although half require indeﬁ  nite maintenance; tox-
icity and costs are modest.20,21 Among several unproven 
theories about its mechanism of action, particularly intriguing 
is the possibility that it increases thrombopoietin levels, just 
as androgens were used to increase erythropoietin levels in 
renal anemia before the advent of the recombinant hormone.22 
This mechanism of danazol action would predict a high 
response rate to thrombopoietin (TPO)-mimetic agents, as 
the more speciﬁ  c puriﬁ  ed hormone would be expected to 
induce higher responses and less toxicity.
Immunosuppressive and cytotoxic therapies are used 
less commonly, mainly to salvage severely affected and 
highly refractory patients.23 Such therapies have included 
cyclophosphamide, azathioprine and vincristine, but newer 
agents such as cyclosporine A and mycophenolate mofetil 
are now often chosen more readily. Enthusiasm in the 1970s 
and 1980s for vinca-loaded platelets and immunoadsorption 
with protein A columns24 has been discarded. Plasma 
exchange can be used in desperate situations, but is not 
usually effective.
Thrombopoietic hormones
For half a century, studies have suggested the existence of 
TPO, a hormone that is the main regulator of the circulating 
platelet mass. When the oncogene c-mpl was discovered, there 
were reasons to suspect it was the receptor for TPO. Using 
different strategies, several investigators virtually simulta-
neously isolated TPO in 1994.25 Recombinant TPO quickly 
entered clinical trials, mainly for chemotherapy-induced 
thrombocytopenia, as did a pegylated truncated analog, 
recombinant human megakaryocyte growth and development 
factor (MGDF). Progress in this ﬁ  eld came to an abrupt halt 
when some volunteers given MGDF developed anti-TPO 
antibodies that caused long-lasting thrombocytopenia.26,27 
Subsequently, new TPO-mimetics have been developed that 
activate the TPO receptor but share no structural homology 
with native TPO, thus carrying no risk of stimulating the 
production of anti-TPO neutralizing antibodies.
Rationale for TPO-mimetics in ITP
Dogma held that the pathophysiology of ITP was simple and 
straightforward. Autoantibodies bind platelets, directing their 
accelerated destruction by reticuloendothelial phagocytes. 
Effective therapies inﬂ  uenced the clearance of coated plate-
lets or reduced autoantibody production.
In clinging to this model, it was necessary to discount or 
disregard evidence accumulated over decades that platelet 
production was also impaired with ITP. Countering the notion 
that a compensatory increase in platelet production should 
accompany ITP, turnover studies employing radio-labeled 
autologous platelets revealed substantial production problems 
in a high percentage of ITP patients.28–31 One mechanism for 
this was the ﬁ  nding that platelet autoantibodies could have 
effects on megakaryocyte maturation and survival.9,32–34 The 
isolation of TPO allowed accelerated comprehension of the 
normal regulation of platelet mass. TPO is constitutively 
produced by the liver and is cleared via binding to receptors 
on circulating platelets and megakaryocytes. Serum TPO 
levels become markedly elevated with thrombocytopenia 
resulting from aplastic anemia or cytotoxic chemotherapy 
because the reduced platelet and megakaryocyte mass 
fail to clear the hormone. In contrast, TPO levels are not 
substantially increased in ITP patients.35,36 This provided 
further rationale for trials of pharmacologic TPO for ITP. 
Impetus was also provided by initial clinical successes with 
ﬁ  rst-generation TPO-mimetic agents in ITP. I have reported 
a patient with a treatment-refractory cyclic variant of ITP 
who responded to MGDF therapy.37 This patient has been 
maintained in remission for 11 years with TPO-mimetic 
therapy.38 Nomura treated four refractory ITP patients with 
MGDF, three of whom responded.39 MGDF also beneﬁ  ted 
HIV-infected chimpanzees with thrombocytopenia and 
platelet autoantibodies.40
Second-generation TPO-mimetic studies
The ﬁ  rst second-generation TPO-mimetic to enter clinical trials 
was romiplostim (AMG-531; Nplate).41 Romiplostim is an 
engineered peptibody with four c-mpl binding peptides linked 
to an immunoglobulin Fc carrier domain. When administered 
to normal volunteers, romiplostim increases platelet counts Biologics: Targets & Therapy 2009:3 154
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in a dose-dependent manner at doses above 1 μg/kg. As with 
TPO and other agents that stimulate platelet production through 
c-mpl binding, the initial rise in platelets occurs in 5 to 7 days, 
peaks at 2 weeks, then falls to baseline by 3 to 4 weeks. Phase II 
and Phase III clinical trials in ITP had eligibility and response 
criteria similar to those of the eltrombopag studies (discussed in 
the following section) and found that 83% of patients showed 
a response, which was sustained and durable in 49%, regard-
less of splenectomy status.42,43 An extension trial has followed 
142 patients for up to 3 years with responses in 90% of patients, 
67% of platelet counts in the target range, and no evidence of 
tachyphylaxis.44 Not only was bleeding reduced, but quality 
of life measurements improved in treated patients.45
Reported adverse events were generally mild and occurred 
no more often than with placebo. There are, however, some 
particular safety concerns that continue to be monitored. 
One is reticulin ﬁ  brosis of the bone marrow; megakaryocyte 
stimulation predictably causes cytokine release (particularly 
TGF-β) that can stimulate marrow ﬁ  broblasts.46 Increased 
reticulin has been seen in 3.5% of treated patients, although 
rarely severe enough to affect blood counts or blood smears. 
It is reversible on stopping the drug (4 of 271 patients stopped 
therapy for this reason), and it is not clear how different the 
incidence is from the ITP patient population in general. Exac-
erbation of thrombotic tendencies is a valid concern with any 
treatment for ITP, but incidence of thromboemboli has not 
been noticeably different from controls. A transient worsening 
of thrombocytopenia on drug withdrawal has been observed 
in almost 10% of patients, but severe bleeding complications 
accompanying this have not been problematic.
Based on the efﬁ  cacy and safety data, the FDA approved 
romiplostim for ITP patients who had failed at least one prior 
therapy, and restricted its use to prescribers and facilities 
registered with the NEXUS program. The approved initial 
dose is 1 μg/kg subcutaneously once weekly, with escalation 
permitted up to 10 μg/kg based on platelet response.
Eltrombopag
Eltrombopag (Promacta®; GlaxoSmithKline) is an orally 
available synthetic non-peptide small molecule that binds 
the transmembrane portion of c-mpl (unlike native TPO or 
romiplostim), thus activating JAK2 and STAT pathways. 
Animal studies are hampered by the fact that rodents and 
dogs do not respond with an increase in platelet count. At high 
doses (2 weeks of 40 mg/kg/day in rodents and 30 mg/kg/day 
in dogs) or with prolonged administration for up to 1 year in 
dogs, the drug was well-tolerated. Cataracts, renal and hepatic 
toxicities were seen in animals after 2 years of use. There 
was no immunogenicity, teratogenicity or carcinogenicity. 
Three chimpanzees doubled their platelet counts after 5 days 
of 10 mg/kg.47
Thirteen Phase I studies enrolled 568 patients, including 
studies of renal or hepatic impaired patients, drug-drug inter-
actions, and cytochrome polymorphisms.48 Peak plasma levels 
are achieved 2 to 6 hours after oral administration and the 
plasma elimination half-life is 21 to 32 hours. In one placebo-
controlled, escalating dose study of 73 men, daily doses of 
30 mg, 50 mg and 75 mg for 10 days raised platelet counts 
beginning at day 8, peaking at day 16, and returning to base-
line day 22.; this time course mirrors other TPO-mimetics. 
Mean initial platelet counts of 239 × 109/L rose by 24%, 43% 
and 50%, respectively. Lower doses (5, 10 and 20 mg) showed 
no difference in platelet counts from placebo.49
The Phase II program included trials for ITP, thrombocy-
topenia with hepatitis C (HCV), and chemotherapy-induced 
thrombocytopenia. Thrombocytopenia is common with 
advanced HCV and contributing factors can include platelet 
sequestration from portal hypertension/hypersplenism, an 
immune reaction (ITP-like), and low TPO production from 
hepatic insufﬁ  ciency. Effective treatments for HCV can be 
myelosuppressive, so exacerbation of the baseline thrombo-
cytopenia frequently prevents optimal therapeutic dosing. 
Seventy-four patients with HCV-related cirrhosis and platelet 
counts of 20 × 109/L to 70 × 109/L were randomized to placebo, 
30 mg, 50 mg or 75 mg of eltrombopag daily. By week four, 
platelet counts above 100 × 109/L were achieved in 0%, 75%, 
79% and 95% of patients, respectively, allowing most patients 
at the two highest doses to tolerate 12-week courses of pegin-
terferon and ribavirin versus 6% on placebo.50
In a Phase II adult ITP study, 118 patients with platelet 
counts less than 30 × 109/L having failed at least one prior 
therapy were randomized to placebo, 30 mg, 50 mg or 75 mg 
of eltrombopag daily. The lowest eltrombopag dose was 
ineffective. More than 80% of patients taking the two higher 
doses had an increase in platelets by day 15; median platelet 
counts of 128 × 109/L and 183 × 109/L were seen on day 43 
(versus 16 × 109/L for placebo patients). Responding patients 
experienced decreased bleeding events. Serious and overall 
adverse events were no more common with eltrombopag 
than with placebo.51
Data from the Phase III trial (RAISE) and an extension 
trial (EXTEND) are recently available from presentations at a 
national meeting, a publication in Lancet, and material provided 
to the FDA by the manufacturer.48,52–55 Included in RAISE were 
again ITP patients with platelets less than 30 × 109/L who had 
failed at least one prior therapy; 197 patients were randomized Biologics: Targets & Therapy 2009:3 155
Eltrombopag for immune thrombocytopenic purpura
in a ratio of 1:2 to placebo or eltrombopag 50 mg daily, with 
escalation to 75 mg daily allowed. The primary endpoint 
of platelet count above 50 × 109/L was achieved by 59% 
on eltrombopag compared to 16% on placebo (p < 0.01). 
Splenectomy status was not a determinant of response. Bleeding 
was reduced in treated patients, even in those who did not meet 
criteria for a platelet response, and several treated patients were 
able to have surgery without the use of rescue medications. More 
than 200 patients have been enrolled in the EXTEND trial, with 
24% maintaining a platelet response for more than 6 months.
Safety data were reported to the FDA on more than one 
thousand exposed individuals of whom more than 300 were ITP 
patients and more than 200 were treated for at least 6 months 
(up to 2 years). The most common adverse events were mild 
(such as headache) and were not more frequent than the inci-
dence with placebo. Phase II studies revealed hepatobiliary 
abnormalities in 9% to 10% of eltrombopag-treated patients 
compared with 8% of placebo patients; in the RAISE trial, 
liver function tests were abnormal in 13% compared with 7% 
of controls. One patient in the trials developed grade 4 hepatic 
dysfunction, had confounding factors as to the etiology of liver 
disease, and died of cardiorespiratory failure and pulmonary 
emboli. A “black box” warning of possible hepatic dysfunction 
appears on the package label. Cataracts developed or worsened 
in 5%, compared with 3% of placebo patients (many patients 
had signiﬁ  cant corticosteroid use). Eleven thromboembolic 
events have been seen on eltrombopag, one fatal, but all 
patients had other risk factors, and the rate did not seem to be 
excessive. Furthermore, platelet function and overall survival 
appeared normal during therapy. The possibility that platelet 
counts could fall below baseline with interruption of the drug 
(“rebound thrombocytopenia”) was analyzed. Such transient 
platelet falls occurred in 30%; in 11%, the platelet count fell 
to 10 × 109/L and more than 10 × 109/L below baseline. While 
serious bleeding was not seen with these falls, administration 
of rescue medications in some could have masked or prevented 
problems. Persistent blood smear abnormalities suggesting 
signiﬁ  cant myeloﬁ  brosis were not encountered in any patient. 
Surveillance bone marrows performed 1 year into treatment 
revealed mild reticulin ﬁ  brosis in 7 of 19 subjects, at least 2 of 
whom had ﬁ  brosis present on pretreatment; this is not clearly 
increased over what has been reported in other ITP patients 
and no patient stopped therapy for this reason.
In comparing eltrombopag to romiplostim, they are structur-
ally totally different, they bind c-mpl at different sites causing 
activation, one is available orally and the other is injected 
subcutaneously. Response rates and durability seem similar in 
studies to date. All TPO-mimetics engender at least theoretic 
concerns about reticulin ﬁ  brosis of the marrow, increasing 
thrombotic risks, and “rebound” worsening of thrombocyto-
penia. These potential problems have not emerged as serious 
problems with either agent. It is not clear whether the relative 
frequencies of these effects differ between one agent and the 
other, because of the small number of patients studied, the fact 
that some of these problems may be related to relative dose, and 
the differing vigor with which some subclinical changes have 
been sought. Possible hepatotoxicity has been more appreciated 
with eltrombopag.
Based on efﬁ  cacy and safety data, the FDA approved 
eltrombopag in November 2008 for ITP patients who had failed 
at least one prior therapy. It is available on a restricted access 
program (Promacta Cares).
Conclusions and future directions
ITP is a relatively common blood disorder related to the 
production of anti-platelet antibodies. Antibody-coated 
platelets are rapidly cleared from the circulation, so a variety 
of therapies have been successful that block the increased 
Table 1 Therapeutic options for immune thrombocytopenic purpura
Corticosteroids for initial therapy
  Prednisone, taper to response
 Dexamethasone,  pulse
Other temporary and “rescue” therapies
  Intravenous immunoglobulin, high dose
  Anti-Rh D (WinRho)
Longer term treatments
 Rituximab
 Danazol
 Splenectomy
Immunosuppressive and cytotoxic therapies
 Azathioprine
 Cyclophosphamide
 Vincristine
 Cyclosporine  A
 Mycophenolate
Desperation and rarely used
 Plasmapheresis
 Protein  A  column  immunoadsorption
 Combination  chemotherapy
  Stem cell transplant strategies
New thrombopoietin mimetics
 Romiplostim
 Eltrombopag
 AKR-501  (experimental)
 LGD-4665  (experimental)Biologics: Targets & Therapy 2009:3 156
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platelet destruction. It is now clear that platelet production 
is also substantially impaired in most patients. The impaired 
production results from antibody effects on megakaryocytes 
and their progenitors, and also to blunted endogenous TPO 
response resulting from ongoing receptor-mediated clearance 
of the hormone. After the cloning of TPO and analogs, there 
were reported therapeutic successes in a few refractory ITP 
patients, but neutralizing antibodies led to the withdrawal of 
ﬁ  rst-generation TPOs from development. Second-generation 
TPO-mimetics are now available that stimulate c-mpl but 
share no homology with the native hormone.
While most patients with ITP do well in the long term on 
previously available therapies, they may suffer signiﬁ  cant toxic-
ities. Second-generation TPO-mimetics have shown responses 
in 50% to 80% of ITP patients with only modest toxicity, and 
thus they offer another therapeutic option. The ﬁ  rst of these 
agents to enter clinical trials and to be approved by the FDA is 
romiplostim, a once weekly subcutaneous peptibody. Eltrom-
bopag is the second FDA-approved TPO-mimetic and has the 
advantage of oral formulation. Newer oral TPO-mimetics in 
clinical trials include AKR-501 and LGD-4665. Beyond ITP, 
TPO-mimetics are being studied in chemotherapy-induced 
thrombocytopenia, myelodysplastic syndromes, hepatitis-
associated thrombocytopenia, and other disorders in which it 
is desirable to stimulate thrombopoiesis. Some concerns persist 
on the potential of these agents to cause increased thrombosis 
risk, rebound thrombocytopenia on drug withdrawal, reticulin 
ﬁ  brosis of the marrow, and induction of malignancy, but these 
have not emerged as major problems in clinical trials. Second-
generation TPO-mimetics are “miracle drugs” for some highly 
refractory ITP patients. Given cost considerations and the need 
for indeﬁ  nite therapy, it will be interesting to see how large a 
niche these agents will ﬁ  nd in the less refractory ITP patient, 
and also what their utility will be in other disorders.
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